Nothing Special   »   [go: up one dir, main page]

TW284688B - - Google Patents

Info

Publication number
TW284688B
TW284688B TW081108934A TW81108934A TW284688B TW 284688 B TW284688 B TW 284688B TW 081108934 A TW081108934 A TW 081108934A TW 81108934 A TW81108934 A TW 81108934A TW 284688 B TW284688 B TW 284688B
Authority
TW
Taiwan
Prior art keywords
compound
formula
melting point
lower melting
group
Prior art date
Application number
TW081108934A
Other languages
English (en)
Original Assignee
Takeda Pharm Industry Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=17938952&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW284688(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharm Industry Co Ltd filed Critical Takeda Pharm Industry Co Ltd
Application granted granted Critical
Publication of TW284688B publication Critical patent/TW284688B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
TW081108934A 1991-11-20 1992-11-09 TW284688B (zh)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP30492491 1991-11-20

Publications (1)

Publication Number Publication Date
TW284688B true TW284688B (zh) 1996-09-01

Family

ID=17938952

Family Applications (1)

Application Number Title Priority Date Filing Date
TW081108934A TW284688B (zh) 1991-11-20 1992-11-09

Country Status (18)

Country Link
US (1) US5534534A (zh)
EP (3) EP0546358B1 (zh)
KR (1) KR100256633B1 (zh)
CN (1) CN1047518C (zh)
AT (2) ATE277602T1 (zh)
AU (1) AU659691B2 (zh)
BR (1) BR1100336A (zh)
CA (1) CA2083305C (zh)
DE (2) DE69221831T2 (zh)
DK (1) DK0546358T3 (zh)
ES (1) ES2104797T3 (zh)
FI (2) FI111604B (zh)
GR (1) GR3025338T3 (zh)
HU (1) HU211608A9 (zh)
MX (1) MX9206634A (zh)
NO (1) NO304408B1 (zh)
NZ (1) NZ245175A (zh)
TW (1) TW284688B (zh)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW284688B (zh) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd
TW272942B (zh) * 1993-02-10 1996-03-21 Takeda Pharm Industry Co Ltd
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
US5753672A (en) * 1994-04-19 1998-05-19 Tanabe Seiyaku Co., Ltd. Imidazopyridine derivatives and process for preparing the same
AU679616B2 (en) * 1994-04-19 1997-07-03 Tanabe Seiyaku Co., Ltd. Imidazopyridine derivatives and process for preparing the same
TW418204B (en) * 1997-03-28 2001-01-11 Dev Center Biotechnology Novel 1,2,4-triazine-5-ketonyl benzene derivatives and the analogs, the preparation, and the pharmaceutical compositions as angiotension II receptor antogonists
US6297239B1 (en) 1997-10-08 2001-10-02 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1058541B1 (en) * 1998-03-04 2004-01-28 Takeda Chemical Industries, Ltd. Sustained-release preparation for aii antagonist, production and use thereof
US7115644B2 (en) * 2002-09-13 2006-10-03 Boehringer Ingelheim Pharmaceuticals Inc. Heterocyclic compounds
US20050031683A1 (en) * 2003-08-04 2005-02-10 Ashish Kapoor Solid pharmaceutical composition
WO2005037821A2 (en) * 2003-10-16 2005-04-28 Teva Pharmaceutical Industries Ltd. Preparation of candesartan cilexetil
US20050175689A1 (en) * 2003-10-27 2005-08-11 Yamanouchi Pharmaceutical Co., Ltd. Coated fine particles containing drug for intrabuccally fast disintegrating tablet
WO2005070398A2 (en) * 2004-01-23 2005-08-04 Ranbaxy Laboratories Limited Pharmaceutical compositions of candesartan cilexetil stabilized with co-solvents
EP1711168A2 (en) * 2004-01-23 2006-10-18 Ranbaxy Laboratories Limited Oral pharmaceutical compositions of candesartan cilexetil
WO2005077941A2 (en) * 2004-02-11 2005-08-25 Teva Pharmaceutical Industries Ltd. Candesartan cilexetil polymorphs
WO2005084670A1 (en) 2004-03-01 2005-09-15 Lek Pharmaceuticals D.D. Pharmaceutical formulation
CZ23090U1 (cs) * 2004-03-25 2011-12-19 Astellas Pharma Inc. Kompozice pevného farmaceutického prípravku solifenacinu nebo jeho soli
MXPA06012702A (es) * 2004-05-05 2007-04-02 Teva Pharma Preparacion de candesartan cilexetil de alta pureza.
US7588779B2 (en) * 2004-05-28 2009-09-15 Andrx Labs, Llc Pharmaceutical formulation containing a biguanide and an angiotensin antagonist
AU2005320672B2 (en) * 2004-12-27 2011-01-06 Astellas Pharma Inc. Stable particulate pharmaceutical composition of solifenacin or salt thereof
EP1835890A2 (en) * 2005-01-06 2007-09-26 Elan Pharma International Limited Nanoparticulate candesartan formulations
JP2007527925A (ja) * 2005-01-14 2007-10-04 テバ ファーマシューティカル インダストリーズ リミティド 粗カンデサルタンシレキセチルの調製
SI1843754T1 (sl) * 2005-01-26 2011-12-30 Lek Pharmaceuticals D.D. Novi farmacevtski sestavek, ki vsebuje kandesartan cileksetil kot lipofilno kristalinično snov
JP2008505935A (ja) * 2005-05-10 2008-02-28 テバ ファーマシューティカル インダストリーズ リミティド 超微粉砕された安定性カンデサルタンシレキセチル及びその調製方法
US7815939B2 (en) * 2005-07-20 2010-10-19 Astellas Pharma Inc. Coated fine particles containing drug for intrabuccally fast disintegrating dosage forms
TW200800299A (en) * 2006-04-27 2008-01-01 Takeda Pharmaceutical Pharmaceutical composition
EP2058010B1 (en) * 2006-08-10 2012-05-02 Takeda Pharmaceutical Company Limited Pharmaceutical composition
WO2008045006A1 (en) * 2006-10-11 2008-04-17 Fako Ilaclari A. S. Formulations of candesartan
ES2301401B1 (es) * 2006-11-28 2009-06-08 Laboratorios Liconsa S.A. Composicion farmaceutica solida estabilizada de candesartan cilexetilo.
EP1952806A1 (en) 2007-02-01 2008-08-06 Helm AG Process for the preparation of adsorbates of candesartan
DE602008002371D1 (de) * 2007-03-08 2010-10-14 Teva Pharma Pharmazeutische zusammensetzung mit candesartan-cilexetil
ES2743784T3 (es) * 2007-03-28 2020-02-20 Takeda Pharmaceuticals Co Composición farmacéutica sólida que comprende un derivado de benzimidazol-7-carboxilato y un agente regulador del pH
KR20090130325A (ko) 2007-04-25 2009-12-22 테바 파마슈티컬 인더스트리즈 리미티드 약학 부형제 복합체
EP2167047A2 (en) * 2007-06-06 2010-03-31 Dexcel Ltd. Process for forming solid oral dosage forms of angiotensin ii receptor antagonists
DE102007052070A1 (de) 2007-10-30 2009-05-07 Tiefenbacher Pharmachemikalien Alfred E. Tiefenbacher Gmbh & Co. Kg Candesartancilexetil
PT2165702E (pt) 2008-09-17 2012-02-07 Helm Ag Composições estáveis e rapidamente dissolvidas de candesartan cilexetil preparadas com granulação húmida
WO2010075347A2 (en) 2008-12-23 2010-07-01 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone
ES2364011B1 (es) 2009-11-20 2013-01-24 Gp Pharm, S.A. Cápsulas de principios activos farmacéuticos y ésteres de ácidos grasos poliinsaturados para el tratamiento de enfermedades cardiovasculares.
ME02663B (me) 2010-10-06 2017-06-20 Glaxosmithkline Llc Derivati benzimidazola kao inhibitori pi3 kinaze
CN102138920A (zh) * 2011-02-24 2011-08-03 海南中济医药科技有限公司 一种含有坎地沙坦酯和氢氯噻嗪的药物组合物及其制备方法
CN102357095A (zh) * 2011-07-12 2012-02-22 迪沙药业集团有限公司 稳定的药物组合物
AU2012335220B2 (en) 2011-11-11 2017-06-01 Pfizer Inc. 2-thiopyrimidinones
EP2928468A4 (en) * 2012-12-05 2016-07-27 Sawai Seiyaku Kk PREPARATION CONTAINING CANDÉSARTAN CILEXÉTIL
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
CA2910112C (en) 2013-04-25 2021-02-16 Kyorin Pharmaceutical Co., Ltd. Solid pharmaceutical composition
EP3008079A4 (en) * 2013-06-11 2017-01-18 Universidade Federal de Minas Gerais Process for preparing amphiphilic peptide derivatives
RS64377B1 (sr) 2015-02-26 2023-08-31 Takeda Pharmaceuticals Co Tableta koja sadrži derivat metoksiuree i čestice manitola
EA034985B1 (ru) 2015-05-05 2020-04-14 Пфайзер Инк. 2-тиопиримидиноны
MX2018004664A (es) 2015-10-16 2018-08-24 Eisai R&D Man Co Ltd Antagonistas de ep4.
CN111617046A (zh) * 2020-07-09 2020-09-04 浙江诺得药业有限公司 阿齐沙坦分散片及其制备工艺
CN112957336A (zh) * 2021-03-03 2021-06-15 广州白云山天心制药股份有限公司 一种稳定的坎地沙坦酯药物固体组合物及其制备方法

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2251199C3 (de) * 1972-10-19 1980-04-10 Hoechst Ag, 6000 Frankfurt Verfahren zur Herstellung von Pyrazolone enthaltenden Tabletten
NZ179623A (en) * 1975-01-06 1978-03-06 Ciba Geigy Pharmaceutical preparation containing a beta-receptor blocking compound, a compound regulating thrombocyte function and optionally an alpha-receptor blocking compund
US4783334A (en) * 1986-01-21 1988-11-08 Chugai Seiyaku Kabushiki Kaisha Stable solid preparation of thiol ester derivative
US4743450A (en) * 1987-02-24 1988-05-10 Warner-Lambert Company Stabilized compositions
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
JPH01308231A (ja) * 1988-06-03 1989-12-12 Takeda Chem Ind Ltd 安定化された医薬組成物および製造法
YU120988A (en) * 1988-06-23 1990-06-30 Lek Tovarna Farmacevtskih Process for preparing new dispersion pills of cimetidine
SU1653780A1 (ru) * 1988-07-25 1991-06-07 Piskov Vyacheslav B Способ получени жидкой формы антгельминтика из группы бензимидазолов с использованием органического растворител
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
EP0411507B1 (en) * 1989-08-02 1994-10-26 Takeda Chemical Industries, Ltd. Pyrazole derivatives, their production and use
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
IL95975A (en) * 1989-10-24 1997-06-10 Takeda Chemical Industries Ltd N-benzyl- 2-alkylbenzimidazole derivatives, their production and pharmaceutical compositions containing them
IL96019A0 (en) * 1989-10-31 1991-07-18 Fujisawa Pharmaceutical Co Imidazole derivatives,processes for the preparation thereof and pharmaceutical compositions containing the same
EP0430300A3 (en) * 1989-12-01 1992-03-25 Takeda Chemical Industries, Ltd. Xanthine derivatives, their production and use
EP0435827A3 (en) * 1989-12-28 1991-11-13 Ciba-Geigy Ag Diaza compounds
CA2036304C (en) * 1990-02-15 2001-04-17 Takehiko Naka Pyrimidinedione derivatives, their production and use
CA2037630C (en) * 1990-03-07 2001-07-03 Akira Morimoto Nitrogen-containing heterocylic compounds, their production and use
AU7759591A (en) * 1990-04-13 1991-11-11 Smithkline Beecham Corporation Substituted benzimidazoles
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
TW284688B (zh) * 1991-11-20 1996-09-01 Takeda Pharm Industry Co Ltd

Also Published As

Publication number Publication date
KR930009606A (ko) 1993-06-21
EP0546358A2 (en) 1993-06-16
NO304408B1 (no) 1998-12-14
CA2083305A1 (en) 1993-05-21
DK0546358T3 (da) 1998-03-09
EP0782852A1 (en) 1997-07-09
KR100256633B1 (ko) 2000-05-15
DE69221831T2 (de) 1998-01-02
AU659691B2 (en) 1995-05-25
CN1047518C (zh) 1999-12-22
NO924417L (no) 1993-05-21
FI20030210A (fi) 2003-02-12
DE69221831D1 (de) 1997-10-02
EP0782852B1 (en) 2004-09-29
ATE157248T1 (de) 1997-09-15
CA2083305C (en) 2003-12-09
CN1072338A (zh) 1993-05-26
DE69233424D1 (de) 2004-11-04
EP0546358B1 (en) 1997-08-27
US5534534A (en) 1996-07-09
GR3025338T3 (en) 1998-02-27
FI925270A (fi) 1993-05-21
DE69233424T2 (de) 2005-02-17
BR1100336A (pt) 2000-04-18
NZ245175A (en) 1994-07-26
FI111604B (fi) 2003-08-29
AU2839192A (en) 1993-05-27
MX9206634A (es) 1993-05-31
ATE277602T1 (de) 2004-10-15
ES2104797T3 (es) 1997-10-16
EP1468683A2 (en) 2004-10-20
HU211608A9 (en) 1995-12-28
FI925270A0 (fi) 1992-11-19
EP1468683A3 (en) 2012-06-06
EP0546358A3 (zh) 1994-03-30
NO924417D0 (no) 1992-11-16

Similar Documents

Publication Publication Date Title
TW284688B (zh)
GB8419963D0 (en) Intermediate compound and method
PL344048A1 (en) Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
GR853064B (zh)
DE3775882D1 (de) Substituierte 6-fluor-4-oxo-1,4-dihydrochinolin-3-carbonsaeuren ; deren derivate; diese verbindung enthaltende pharmazeutische zubereitungen und verfahren zur herstellung dieser verbindungen.
IL66341A (en) Pyrrolidin-2-oxo-1-acetamides,their manufacture and pharmaceutical compositions containing them
NZ503912A (en) Piperidinylaminomethyl trifluoromethyl cyclic ether compounds and their use as substance P antagonists
TW340115B (en) Triazine derivatives and pharmaceutical composition for hepatitis the invention relates to triazine derivatives and pharmaceutical composition for hepatitis
IL75115A0 (en) Beta-carboline-3-oxadiazolyl derivatives,process for the preparation thereof and pharmaceutical compositions containing the same
JPS56133267A (en) Novel 3,4,5-trihydroxypiperidine compound
PH20327A (en) New substituted 1,4-dihydropyridines and pharmaceutical compositions containing the same
PT74261A (pt) Neue carbonsaeureamide ihre herstellung und ihre verwendung als arzneimittel
EA200300044A1 (ru) Новые замещенные фталиды, способ их получения и содержащие их фармацевтические композиции
AU4872793A (en) New ellipticine compounds, a process for their preparation and pharmaceutical compositions containing them
EG17311A (en) Method of preparation for composition active against mites white fly and thrips pharmaceutical composition and new benzoylurea compounds
MY108849A (en) Novel compound
GR3021303T3 (en) Benzimidazoles, pharmaceutical compositions containing them and process for their preparation
SE8303913D0 (sv) Heterocykliska foreningar
IE830469L (en) Fungicidal cyanopropenoates
ZA872664B (en) Six-membered heterocyclic derivatives of n'-substituted-n,n'-diacylhydrazines
JPS5753488A (en) 2-o and 5-o substituted 1,4;3,6- dianhydrohexitol mononitrate compound, manufacture and drug composition
ATE23147T1 (de) Ungesaettigte verbindungen, ihre herstellung und anwendung.
ES8401966A1 (es) Procedimiento para preparar las (2,3-dihidro(1,4-benzodioxin-2-il) alcoil) piperidin-4-il-(n-ciano-n'-r) guanidinas.
IE812607L (en) Heterobicyclic compounds
GR3001003T3 (en) Novel pregnane derivatives, processes for their preparaton and pharmaceutical compositions containing same

Legal Events

Date Code Title Description
MK4A Expiration of patent term of an invention patent